Compare GLDD & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLDD | ORIC |
|---|---|---|
| Founded | 1890 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 814.6M | 783.0M |
| IPO Year | 2006 | 2020 |
| Metric | GLDD | ORIC |
|---|---|---|
| Price | $13.37 | $8.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 400.7K | ★ 1.4M |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.27 | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $834,599,000.00 | N/A |
| Revenue This Year | $12.71 | N/A |
| Revenue Next Year | $4.77 | N/A |
| P/E Ratio | $11.22 | ★ N/A |
| Revenue Growth | ★ 12.53 | N/A |
| 52 Week Low | $7.51 | $3.90 |
| 52 Week High | $14.02 | $14.93 |
| Indicator | GLDD | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 55.64 | 27.80 |
| Support Level | $13.28 | $7.98 |
| Resistance Level | $13.60 | $8.62 |
| Average True Range (ATR) | 0.36 | 0.59 |
| MACD | -0.06 | -0.07 |
| Stochastic Oscillator | 43.10 | 6.52 |
Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The Company is also fully engaged in expanding its core business into the offshore energy industry. Dredging involves the enhancement or preservation of the navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand, or rock. Company work generally is to performed in coastal waterways and deep water ports. Its project portfolio includes Coastal Restoration, Coastal Protection, Ports and Harbors, International, and Inland Dredging.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.